Skip to Main Content

Author Details

Marc Hafner
Harvard Medical School
2009
40
24
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36410439Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action.J Biol Chem2023
36410439Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action.J Biol Chem2023
37277530An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.Nat Cancer2023
37542042Proteomic profiling across breast cancer cell lines and models.Sci Data2023
37542042Proteomic profiling across breast cancer cell lines and models.Sci Data2023
37277530An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.Nat Cancer2023
34544753RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy.Cancer Discov2022
36376301Multiplexed and reproducible high content screening of live and fixed cells using Dye Drop.Nat Commun2022
35585485Evaluation of statistical approaches for association testing in noisy drug screening data.BMC Bioinformatics2022
35731938Growth-rate model predicts in vivo tumor response from in vitro data.CPT Pharmacometrics Syst Pharmacol2022
36130016Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.Sci Transl Med2022
35983994EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS <sup>G12D</sup> tumor development and propagation.Elife2022
34850112PharmacoDB 2.0: improving scalability and transparency of in vitro pharmacogenomics analysis.Nucleic Acids Res2022
34544753RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy.Cancer Discov2022
35585485Evaluation of statistical approaches for association testing in noisy drug screening data.BMC Bioinformatics2022
35731938Growth-rate model predicts in vivo tumor response from in vitro data.CPT Pharmacometrics Syst Pharmacol2022
36130016Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.Sci Transl Med2022
35983994EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS <sup>G12D</sup> tumor development and propagation.Elife2022
36376301Multiplexed and reproducible high content screening of live and fixed cells using Dye Drop.Nat Commun2022
34850112PharmacoDB 2.0: improving scalability and transparency of in vitro pharmacogenomics analysis.Nucleic Acids Res2022
34223192Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients.Nat Cancer2021
34223192Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients.Nat Cancer2021
30858179A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers.J Biol Chem2019
31302153A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines.Cell Syst2019
31178407Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.Cell Chem Biol2019
30858179A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers.J Biol Chem2019
30956147Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries.Cell Chem Biol2019
31353221Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility.Cell2019
31307887Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.Bioorg Med Chem Lett2019
31302153A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines.Cell Syst2019
31353221Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility.Cell2019
31178407Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.Cell Chem Biol2019
31307887Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.Bioorg Med Chem Lett2019
30956147Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries.Cell Chem Biol2019
29199020The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations.Cell Syst2018
29199020The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations.Cell Syst2018
28591115Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics.Nat Biotechnol2017
28591115Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics.Nat Biotechnol2017
28628199Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells.Curr Protoc Chem Biol2017
28628201Designing Drug-Response Experiments and Quantifying their Results.Curr Protoc Chem Biol2017
29084964Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling.Nat Commun2017
29112189Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics.Sci Data2017
29065900GRcalculator: an online tool for calculating and mining dose-response data.BMC Cancer2017
29084964Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling.Nat Commun2017
29065900GRcalculator: an online tool for calculating and mining dose-response data.BMC Cancer2017
29112189Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics.Sci Data2017
28628199Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells.Curr Protoc Chem Biol2017
28628201Designing Drug-Response Experiments and Quantifying their Results.Curr Protoc Chem Biol2017
27135972Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs.Nat Methods2016
28413689L1000CDS<sup>2</sup>: LINCS L1000 characteristic direction signatures search engine.NPJ Syst Biol Appl2016
  • 1 - 50 of 80

Recommended Authors

??smund Flobak
Norwegian University of Science and Technology
Career Start Year 2015
Number of shared co-authors 0
Mehdi Bouhaddou
J. David Gladstone Institutes
Career Start Year 2014
Number of shared co-authors 6
In Sock Jang
Celgene Corporation
Career Start Year 2013
Number of shared co-authors 1
Wail Ba-Alawi
Princess Margaret Cancer Centre, University Health Network, University Ave.
Career Start Year 2013
Number of shared co-authors 4
Nehme El-Hachem
Centre Hospitalier Universitaire Sainte-Justine Research Centre
Career Start Year 2011
Number of shared co-authors 3
Bhavneet Bhinder
Memorial Sloan Kettering Cancer Center, USA Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 0
Murat Iskar
Friedrich Miescher Institute for Biomedical Research
Career Start Year 2010
Number of shared co-authors 0
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Sam Michael
National Center for Advancing Translational Sciences, National Institutes of Health
Career Start Year 2008
Number of shared co-authors 0
Neda Bagheri
University of Washington
Career Start Year 2007
Number of shared co-authors 1
Jing Tang
University of Helsinki
Career Start Year 2007
Number of shared co-authors 3
James C Costello
University of Colorado Anschutz Medical Campus
Career Start Year 2006
Number of shared co-authors 4
Jacob Stewart-Ornstein
Hillman Cancer Center, University of Pittsburgh School of Medicine
Career Start Year 2005
Number of shared co-authors 0
Armand Bankhead
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 2005
Number of shared co-authors 1
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 0
Adam A Margolin
Icahn School of Medicine
Career Start Year 2004
Number of shared co-authors 7
Julio Saez-Rodriguez
Institute of Computational Biomedicine, Heidelberg University
Career Start Year 2004
Number of shared co-authors 11
Anang A Shelat
St. Jude Children's Research Hospital
Career Start Year 2003
Number of shared co-authors 0
Steven J Altschuler
Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 2001
Number of shared co-authors 0
Lani F Wu
Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 2001
Number of shared co-authors 0
Kevin A Janes
University of Virginia
Career Start Year 2001
Number of shared co-authors 1
Mariano J Alvarez
Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center
Career Start Year 2000
Number of shared co-authors 4
Kerby Shedden
University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 1
Paul A Clemons
Broad Institute
Career Start Year 1999
Number of shared co-authors 4
Ranadip Pal
Texas Tech University
Career Start Year 1999
Number of shared co-authors 0
Mathew J Garnett
Wellcome Sanger Institute
Career Start Year 1998
Number of shared co-authors 4
David de Graaf
Syntimmune Inc.
Career Start Year 1995
Number of shared co-authors 2
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 6
Andrea Califano
Columbia University
Career Start Year 1993
Number of shared co-authors 8
Marc Ferrer
National Institutes of Health, National Center for Advancing Translational Sciences
Career Start Year 1992
Number of shared co-authors 1

Collaborators

Peter K Sorger
Co-authored papers 19
Mario Niepel
Co-authored papers 14
Mirra Chung
Co-authored papers 9
Kartik Subramanian
Co-authored papers 6
Jeremy L Muhlich
Co-authored papers 5
Caitlin E Mills
Co-authored papers 5
Avi Ma'ayan
Icahn School of Medicine at Mount Sinai
Co-authored papers 4
Elizabeth H Williams
Co-authored papers 4
Laura M Heiser
Oregon Health Sciences University
Co-authored papers 3
Nathanael S Gray
Harvard Medical School
Co-authored papers 3
Joe W Gray
Oregon Health and Science University
Co-authored papers 3
James E Korkola
Co-authored papers 3
Zichen Wang
Icahn School of Medicine at Mount Sinai
Co-authored papers 3
Qiaonan Duan
Co-authored papers 3
Todd R Golub
Broad Institute of MIT and Harvard
Co-authored papers 3
Aravind Subramanian
Co-authored papers 3
Mario Medvedovic
Co-authored papers 3
Nicholas A Clark
Co-authored papers 3
Nicolas F Fernandez
Co-authored papers 2
Andrew D Rouillard
Co-authored papers 2
Marc R Birtwistle
Clemson University.
Co-authored papers 2
Marcin Pilarczyk
Co-authored papers 2
Benjamin Haibe-Kains
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Michal Kouril
Co-authored papers 2
Araz Jakalian
Co-authored papers 1
Sherry L Jenkins
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Co-authored papers 1
Caty Chung
Co-authored papers 1
Christopher J Bakkenist
UPMC Hillman Cancer Center, University of Pittsburgh
Co-authored papers 1
Kelly M Haston
Co-authored papers 1
Heidi S Feiler
Co-authored papers 1
Release 1.2